Search for: "In Re Bayer Aktiengesellschaft"
Results 1 - 13
of 13
Sorted by Relevance
|
Sort by Date
11 Nov 2007, 1:28 pm
In Re Bayer Aktiengesellschaft, Federal U.S. [read post]
24 May 2007, 3:07 pm
In re Bayer Aktiengesellschaft, No. 2006-1279 (Fed. [read post]
25 May 2007, 5:00 am
In re Bayer Aktiengesellschaft, Appeal No. 2006-1279 (May 24, 2007) [precedential].The Examining Attorney relied on numerous NEXIS excerpts and two dictionary definitions in which ASPIRINA was defined as aspirin. [read post]
20 Apr 2022, 10:40 am
” In re Bayer Aktiengesellschaft, 488 F.3d 960, 963 (Fed. [read post]
28 Mar 2017, 9:03 am
” In re Bayer Aktiengesellschaft, 488 F.3d 960,970 (Fed. [read post]
24 May 2007, 1:36 pm
While the evidence of record was conflicting as to whether ASPIRINA was descriptive, given the deferential standard of review, the panel majority affirmed the decision to deny registration to Bayer.Judge Newman dissented, and would have given more weight to the fact that ASPIRINA is a registered mark in 34 foreign countries, and the fact that the applicant was policing use of the term online.More details of In re Bayer Aktiengesellschaft after the jump. [read post]
10 Jan 2008, 7:39 am
For example, In Re Bayer Aktiengesellschaft, Serial No. 78/212,751 (US Ct. [read post]
22 Jun 2018, 3:31 pm
Princeton Vanguard, 786 F.3d at 964(citing In re Hotels.com, LP, 573 F.3d 1300, 1301 (Fed.Cir. 2009)); In re Bayer Aktiengesellschaft, 488 F.3d 960,964 (Fed. [read post]
25 Apr 2014, 7:38 pm
See In re Bayer Aktiengesellschaft, 488 F.3d 960, 82 USPQ2d 1828, 1831 (Fed. [read post]
4 Apr 2012, 8:53 am
” In re Bayer Aktiengesellschaft, 488 F.3d 960, 963 (Fed. [read post]
16 Jun 2010, 3:02 pm
Novartis Animal Health US, Inc (Docket Report) US: Finding ORGANIC ASPIRIN deceptively misdescriptive of and deceptive for dietary supplements, TTAB sustains Bayer opposition: Bayer Aktiengesellschaft v. [read post]
9 Nov 2015, 4:00 am
The Federal Court of Appeal in Bayer Schering Pharma Aktiengesellschaft v. [read post]
12 Apr 2012, 10:11 am
In re Bayer Aktiengesellschaft, 488 F.3d 960, 970 (Fed. [read post]